Trouble reading this email? View it in your browser
European Federation of Pharmaceutical industries and associations
   

EFPIA Newsletter 12 March 2026

 
 
 
   

Blogs
 
Thumbnail

Public-private partnerships: How the Innovative Health Initiative (IHI) is driving progress...
12 March 2026

From AMR and AI to big data and regulatory innovation, IHI projects are tackling Europe’s priority health challenges... Read more
 
 
 
   

Cancer care is becoming more efficient – Better outcomes without escalating costs (Guest blog)

Cancer places a substantial burden on European societies. It accounts for 23% of all deaths and around 17% of disability-adjusted life years (DALYs), making it one of the most significant causes of the overall disease burden. Against this backdrop, cancer is often thought of as a growing financial threat to health systems. Yet the Comparator Report on Cancer in Europe 2025 by the Swedish Institute for Health Economics (IHE) commissioned by the EFPIA Oncology Platform tells a more nuanced and more encouraging story.

Europe is achieving better cancer outcomes without cancer overwhelming health budgets. In fact, cancer care is delivering increasing value for money.

Discover the second blog in the serie.
 
 
 
 
   

Joint industry statement on the AI omnibus - Administrative clean-up or a boost for Europe’s AI competitiveness?

The fast-paced negotiations on the AI omnibus risk becoming a missed opportunity to address the challenges industrial companies, from healthcare and manufacturing to energy and automotive, face when implementing the AI Act in practice.

Read the full statement here.
 
 
 
 
   

Events
 

Improving Europe’s water quality - How can the revised UWWTD be implemented fairly and effectively?...
17 March 2026 (Brussles, Belgium)

Join this Euractiv Hybrid Conference to explore how the revised Urban Wastewater Treatment Directive and its EPR scheme... Read more

J&J | The essentials of partnering with a pharma company
19 March 2026 (Utrecht & Virtual)

Discover what it takes to build successful collaborations with pharmaceutical companies and accelerate your innovation... Read more

DIA Europe 2026
24 March 2026 (Rotterdam, Netherlands)

Join the DIA Europe 2026 in March to explore how Europe can bring and keep innovation into the system to deliver better... Read more

Europe’s Choice: Investing in sustainable health systems
21 April 2026 (Brussels, Belgium)

At a time when health budgets are strained, public finances are under pressure, the health workforce crisis is deepening,... Read more
 
 
 
   

What we are reading
 
Can Europe restore its edge in healthcare innovation?
On 10 March 2026 (Financial Times)

Europe’s problem is not any lack of scientific excellence, but rather a policy environment that restricts its impact.... Read more
New guidance on the conduct of clinical trials during public health emergencies in the EU
On 05 March 2026 (European Medicines Agency)

The Accelerating Clinical Trials in the EU (ACT EU) initiative has published a draft guidance document outlining... Read more
Europe needs a Life Course Immunisation Strategy
On 02 March 2026 (Vaccines Today)

Immunisation is widely recognised as one of the most effective public health interventions, with vaccination serving... Read more

About the EFPIA newsletter

The European Federation of Pharmaceutical Industries and Associations (EFPIA) represents the pharmaceutical industry operating in Europe. Through its direct membership of 37 national associations and 40 leading pharmaceutical companies, EFPIA is the voice on the EU scene of 1,900 companies committed to researching, developing and bringing to patients new medicines that will improve health and the quality of life around the world.
Tel: +32 (0)2 626 25 55
E-mail:Communications@efpia.eu
EFPIA 2026 All rights reserved Disclaimer